替比夫定治疗失代偿期乙肝肝硬化2年随访观察(2)
![]() |
第1页 |
参见附件。
[2] Leung N,Peng CY,Hann HW,et al.Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B:a randomized international study of entecavir versus adefovir.Hepatology,2009,49(1):72-79.
[3] Gisbert JP,Chaparro M,Esteve M.Review article:prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease.Aliment Pharmacol Ther,2011,33(6):619-633.
[4] 中华医学会肝病学分会、感染病学分会.慢性乙型肝炎防治指南.中华肝脏病杂志,2005,13:881-891.
[5] Papatheodoridis GV,Manolakopoulos S,Dusheiko G,et al.Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.Lancet Infect Dis,2008,8:167-178.
[6] 陈从新,刘波,郭顺明,等.拉米夫定治疗乙型肝炎肝硬化的临床观察.胃肠病学和肝病学杂志,2007,16(2):150-151.
[7] Amarapurkar DN.Telbivudine:Anewtreatment for chronic hepatitis B.World J Gastroenterol,2007,(13):6150-6155.
[8] Tacke F,Trautwein C.Hepatitis B goes globe:Telbivudine as a new treatment option.Hepatology,2008,47(5):1786-1787.
[9] Hou J,Yin YK,Xu D,et al.Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B:Results at 1 year of a randomized,double-blind trial.Hepatology,2008,47(2):447-454.
[10] Ching-Lung Lai,Edward Gane,Yun-Fan Liaw,et al.Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B.N Engl J Med,2008,358:1517-1518.
您现在查看是摘要介绍页,详见PDF附件。